Endometrial Cancer Trial, Recruiting NCT06256224 Sponsor: Ruijin Hospital Condition: Endometrial Cancer
Back to Endometrial Cancer

Endometrial Cancer Trial, Recruiting

NCT06256224
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are a woman aged 18 or older
  • You have been recently diagnosed with a type of cervical cancer called squamous cell carcinoma that has not been treated before
  • Your cancer is locally advanced (at a certain stage of spread within the pelvic area) but has not spread to distant parts of the body
  • You are generally in good health and able to carry out daily activities, with no major organ problems
  • You are willing and able to give your written agreement to take part in the trial

Who may not be able to join:

  • You have a history of a condition that weakens your immune system
  • You have any health condition that the research team feels could put you at higher risk from the treatment (confirm with trial site)
  • You have previously received, or are currently receiving, a type of cancer treatment called a PD-1 or PD-L1 immunotherapy (a specific kind of treatment that uses the immune system to fight cancer)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Haoping Xu, Ruijin Hospital

Phone: 8618801970632

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Registry
ClinicalTrials.gov
Start date
2 February 2024
Est. completion
31 December 2028

Where this trial is recruiting

🇨🇳 China

Primary endpoints

2-year progression-free survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov